DK3827101T3 - Gensignaturer til forudsigelse af melanommetastase og patientprognose - Google Patents

Gensignaturer til forudsigelse af melanommetastase og patientprognose Download PDF

Info

Publication number
DK3827101T3
DK3827101T3 DK19787488.6T DK19787488T DK3827101T3 DK 3827101 T3 DK3827101 T3 DK 3827101T3 DK 19787488 T DK19787488 T DK 19787488T DK 3827101 T3 DK3827101 T3 DK 3827101T3
Authority
DK
Denmark
Prior art keywords
gene signatures
patient prognosis
melanoma metastasis
predict
predict melanoma
Prior art date
Application number
DK19787488.6T
Other languages
Danish (da)
English (en)
Inventor
Alexander Meves
Domenico Bellomo
Original Assignee
Skylinedx B V
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skylinedx B V, Mayo Found Medical Education & Res filed Critical Skylinedx B V
Application granted granted Critical
Publication of DK3827101T3 publication Critical patent/DK3827101T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/166Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19787488.6T 2018-07-25 2019-07-25 Gensignaturer til forudsigelse af melanommetastase og patientprognose DK3827101T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862703221P 2018-07-25 2018-07-25
US201862750294P 2018-10-25 2018-10-25
US201862778777P 2018-12-12 2018-12-12
PCT/NL2019/050487 WO2020022895A2 (en) 2018-07-25 2019-07-25 Gene signatures for predicting metastasis of melanoma and patient prognosis

Publications (1)

Publication Number Publication Date
DK3827101T3 true DK3827101T3 (da) 2023-12-11

Family

ID=68242821

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19787488.6T DK3827101T3 (da) 2018-07-25 2019-07-25 Gensignaturer til forudsigelse af melanommetastase og patientprognose

Country Status (11)

Country Link
US (2) US12473599B2 (https=)
EP (1) EP3827101B1 (https=)
JP (1) JP7633159B2 (https=)
KR (1) KR20210044233A (https=)
CN (1) CN113039289B (https=)
AU (1) AU2019310636B2 (https=)
CA (1) CA3107401A1 (https=)
DK (1) DK3827101T3 (https=)
ES (1) ES2966015T3 (https=)
IL (1) IL280377A (https=)
WO (1) WO2020022895A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102751357B1 (ko) * 2021-07-16 2025-01-06 한림대학교 산학협력단 구강암의 임프절 전이 예측과 관련된 유전자군
WO2023107329A1 (en) * 2021-12-08 2023-06-15 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
AU2022406744A1 (en) * 2021-12-08 2024-07-11 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
WO2024108191A1 (en) * 2022-11-18 2024-05-23 University Of Virginia Patent Foundation Machine learning approach to predicting lymph node metastases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
US20070154889A1 (en) 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20060136145A1 (en) 2004-12-20 2006-06-22 Kuo-Jang Kao Universal reference standard for normalization of microarray gene expression profiling data
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
AU2007292219B2 (en) 2006-09-06 2014-04-24 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
AU2008247502A1 (en) 2007-05-04 2008-11-13 Dermtech International Diagnosis of melanoma by nucleic acid analysis
EP2191020A2 (en) 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
US20120128667A1 (en) 2009-05-01 2012-05-24 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
AU2011305696A1 (en) 2010-09-20 2013-05-02 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
WO2014077915A1 (en) 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
WO2016025717A1 (en) * 2014-08-14 2016-02-18 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
MX388345B (es) 2016-05-10 2025-03-19 Mayo Found Medical Education & Res Métodos y materiales para estadificar cáncer de piel y seleccionar tratamiento.

Also Published As

Publication number Publication date
CN113039289A (zh) 2021-06-25
US12473599B2 (en) 2025-11-18
JP7633159B2 (ja) 2025-02-19
EP3827101B1 (en) 2023-11-08
WO2020022895A2 (en) 2020-01-30
NZ771988A (en) 2025-02-28
AU2019310636B2 (en) 2025-06-26
EP3827101A2 (en) 2021-06-02
IL280377A (en) 2021-03-25
ES2966015T3 (es) 2024-04-17
KR20210044233A (ko) 2021-04-22
US20260071281A1 (en) 2026-03-12
WO2020022895A3 (en) 2020-04-02
CA3107401A1 (en) 2020-01-30
US20210301353A1 (en) 2021-09-30
JP2021531831A (ja) 2021-11-25
CN113039289B (zh) 2025-11-07
AU2019310636A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
DK3507386T3 (da) Fremgangsmåder og indretning, der øger effektiviteten af sekvensering med binding
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3827101T3 (da) Gensignaturer til forudsigelse af melanommetastase og patientprognose
DK3454844T3 (da) Behandling af tyktarmskræft med en kombination af hdac-inhibitoren hbi-8000 og en pd-l1-inhibitor
EP3762507A4 (en) GENERALIZED STOCHASTIC SUPER-RESOLUTION SEQUENCING
DK3797182T3 (da) Elektrolyseenhed og fremgangsmåde til drift af elektrolyseenhed
DK3153398T3 (da) Flydende struktur og fremgangsmåde til installation heraf
DK3553180T3 (da) Fremgangsmåde til konstruktion af enkeltcellesekventeringsbibliotek og anvendelse deraf
DK3103046T3 (da) Biomarkør-signaturfremgangsmåde og apparater og kits deraf
DK3877376T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3820906T3 (da) Multispecifikke wnt-surrogatmolekyler og anvendelser deraf
DK3318001T3 (da) Fremgangsmåder og indretninger til håndtering af hash-tree-baserede datasignaturer
DK3672919T3 (da) Anlæg og fremgangsmåde til fremstilling af cementklinker
EP3867405A4 (en) EPIGENETIC BIOMARKER AND USES THEREOF
DK3607065T3 (da) Fremgangsmåde og kit til konstruktion af nukleinsyrebibliotek
DK3231405T3 (da) Fremgangsmåde til at forudsige udskillelser og indretning hertil
EP3651709A4 (en) PORTABLE MULTIMEDIA CONTENT BOX
DK3595665T3 (da) Dobbelthæmmere af magl og faah
EP3732816C0 (en) SECURE INSTALLATION OF APPLICATION KEYS
DK3130721T3 (da) Flerlagsrenoveringsbygningselement og udvendig overflade på bygning
DK3356616T3 (da) Belyst keramikflise og fremgangsmåde til fremstilling deraf
DK4218753T3 (da) Ny lipasehæmmer og anvendelser deraf
DK3245204T3 (da) Små molekyler til behandling af primær cancer og cancermetastase
DK3259599T3 (da) Biomarkører til diagnosticering og prognose af ektatiske hornhindelidelser